Live Breaking News & Updates on Jacqui Stockley

Arquer Diagnostics ADXBLADDER Becomes First Bladder Cancer Urine Test To Undergo Rigorous Clinical Trials In USA
First patients recruited for bladder cancer recurrence monitoring study
News provided by
Share this article
SUNDERLAND, England, July 27, 2021 /PRNewswire/
ADXBLADDER has become the first new generation urinary biomarker test for bladder cancer to undergo rigorous clinical trials in the USA in decades. The innovative and highly accurate test, developed by UK company Arquer Diagnostics, is already approved for use across Europe.
ADXBLADDER is now being evaluated in a bladder cancer recurrence monitoring study in the US. With results of the study expected by the end of 2021, Arquer Diagnostics hopes to make a 510(k) premarket submission to the US Food and Drug Administration (FDA) to gain clearance from the organisation for ....

United States , United Kingdom , Aashish Kamat , Jacqui Stockley , European Association Of Urology , Oncology Trial Management Organisation , National Cancer Institute Comprehensive Center , Drug Administration , Karmanos Cancer Institute Wayne State University , Md Anderson Cancer Center , Cancer Research , Carolina Urologic Research Centre , American Cancer Society , Arquer Diagnostics , Chief Scientific Officer , Minichromosome Maintenance Complex Component , Uro Oncology Trial Management Organisation , Karmanos Cancer , Wayne State University , European Association , Negative Predictive Value , Positive Predictive Value , Urologic Oncology , Cancer Center , Neal Shore , Medical Director ,